# IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors

> clinical trial · VERIFIED · 2026-07-10

Status: NOT_YET_RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Relapsed Solid Tumor Malignancies

- Company: National Cancer Institute (NCI)
- Sector: Relapsed Solid Tumor Malignancies
- Primary source: https://clinicaltrials.gov/study/NCT07672483

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.